Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | CPA2 | P48052 | 1/20 | 0.42 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11113260 | 1.00 | ACE (0.53) | ACEMMELNPEPERAP2ERAP1 | |
| SCHEMBL4428771 | 0.87 | ACE (0.51) | ACELNPEPERAP2ERAP1ANPEP | |
| SCHEMBL661267 | 0.86 | ACE (0.65) | ACEMMELNPEPERAP2ERAP1 | |
| SCHEMBL5870137 | 0.86 | ACE (0.65) | ACEMMELNPEPERAP2ERAP1 | |
| SCHEMBL7267746 | 0.86 | ACE (0.65) | ACEMMELNPEPERAP2ERAP1 | |
| SCHEMBL7276530 | 0.84 | CTSC (0.53) | ACEMMELNPEPERAP2ERAP1 | |
| SCHEMBL7268746 | 0.84 | CTSC (0.53) | ACEMMELNPEPERAP2ERAP1 | |
| SCHEMBL6064942 | 0.83 | ANPEP (0.42) | ACELNPEPERAP2ERAP1CPB2 | |
| SCHEMBL6064398 | 0.80 | ACE (0.70) | ACEMMELNPEPERAP2ERAP1 | |
| Lysine SCHEMBL6420000 | 0.79 | ACE (0.50) | ACEMMELNPEPERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2285399-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 FOR TREATING LIPID DISORDERS | Schering Corporation (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009143367-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ACE 357/4885MME 978/4885LNPEP 3414/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ACE 126/4885MME 125/4885LNPEP 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.